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ABSTRACT 
The present investigation was undertaken to perform structural, physicochemical characterization and to estimate the harpagoside in dried root 
extract and flavoured powder formulations of harpagophytum procumbens (devils claw). The extraction of harpagoside from the root extract was 
carried out using different solvents and the harpagoside content was estimated using an RP-HPLC-PDA method. The HPLC analysis was carried 
out using methanol: 0.02% formic acid (60:40 v/v) as the mobile phase, pumped at flow rate of 1mL/min through C18 column (Kinetex XB, 
150x4.6mm, 5µ). The structural and physicochemical characterization of the root extract was performed using FT-IR, DSC and SEM analysis. 
Flavoured powder formulations (effervescent and non-effervescent) of the root extract were prepared and the harpagoside content was 
estimated by HPLC method. Higher percentage of harpagoside (1.6 %) was extracted with water as extraction solvent when compared to 
methanol and methanol: water (50:50 v/v). The developed RP-HPLC-PDA method resulted in shorter elution time (harpagoside was eluted at 
5.3min) and the method was linear with good regression coefficient (R2>0.998) within the concentration range tested (0.2-4µg/mL). The FT-IR 
spectra of root extract showed the presence of characteristic peaks corresponding to the harpagoside and the results from photomicrographs 
and SEM analysis revealed spherical morphology of the particles in the extract. The prepared powdered formulations readily dispersed and 
dissolved in water and showed more than 98% of harpagoside content even after 6months time period indicating the stability of the 
formulations. Overall, the results from the present investigation can form basis to establish standardization parameters for formulations 
containing root extract of devil’s claw.  
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The utilization of herbal formulations as a part of health care 
management was still in practice even with the advancement 
of modern medicine 1. Moreover, the use of the herbal 
formulations had increase rapidly in the recent years and 
more than 80 percent of people around the world are found 
to be depend on herbal formulations for their health care 2. 
The major reasons that can be attributed for the widespread 
use of these herbal formulations are the ease of availability 
through online markets and due to the misconceptions 
regarding their safety aspects 1.  
This increase in utilization of herbal products by people had 
presented new challenges to the regulatory authorities i.e. 
the establishment of safety and efficacy parameters for the 
herbal formulations 3. The general prevalence of concept that 
these formulations are safe and devoid of any side effects is 
untrue 1. Also, most of the herbal formulations are 
introduced into the online market by different companies 
claiming that their products are standardized and safe, but 
the authenticity of such claims needs to be scrutinized 4. 
Several studies reported that the most of the herbal 
formulations available through the online market contains 
heavy metals in concentrations more than their permissible 
levels along with the detectable levels of other synthetic 
drugs to enhance the products efficacy 5, 6. These factors 
presence the need to standardize these herbal formulations 
in terms of their quality, quantity, safety and efficacy. 
Standardization of the herbal formulations involves 
establishment of a set of parameters that defines the 
qualitative and quantitative characteristics which can be 
used to assess the products quality, safety and efficacy 
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parameters 7. The process of standardization includes 
several steps of evaluation like the organoleptic, 
pharmacognostic, phytochemical evaluations etc. and among 
them the phytochemical evaluation is regarded as the major 
step as it defines the activity of the formulation 8.  
The major hurdle associated with the standardization is the 
complexity of the herbal formulations. The herbal 
formulations usually consists of materials of plant origin 
either in crude form or extracted or processed forms mixed 
with various excipients 7. Often this material of the plant 
origin is prone to lot of variations like the source of the raw 
material, its storage conditions, drying rates etc. that had 
direct influence on the activity of the formulation 9. 
Moreover, many of the herbal formulations exist as a 
complex mixture making the separation and analysis of 
individual components a challenging task. However, with the 
development of modern chromatographic techniques like 
TLC, HPTLC, HPLC, GC, etc. and spectroscopic methods like 
FT-IR, NMR, Mass spectroscopy etc. it had become possible 
to separate, analyse and establish the composition of the 
herbal formulations and to detect the extent of adulterations 
in the formulations 7.  
One of the example of such herbal formulations with 
multiple constituents is the formulations containing dried 
root extract of Harpagophytum procumbenes commonly 
known as devil’s claw 10. The root extract is known to 
possess anti-inflammatory and analgesic properties mainly 
due to the iridoid glycosides that are present in the 
secondary roots 11, 12. Along with the harpagoside, which is 
the main iridoid glycoside (Figure 1) it also contains 
harpagide and procumbide the other two iridoid glycosides, 
some flavonoids, sugars, phenolic acids etc 13. Although the 
extract contains different types of constituents, the 
therapeutic activity is believed to be due to the iridoid 
glycosides and the harpagoside is considered as the major 
compound 14.  
 
Figure 1: Structure of Harpagoside 
Studies on the clinical efficacy of root extract 15, 16 also 
demonstrated that anti-inflammatory activity of the extract 
mainly depends on the harpagoside content. The European 
pharmacopeia also specifies that the dried root extract 
should contain a minimum 1.5 percent of harpagoside 17. The 
root extract is widely available through online markets in 
form of tablets, capsules, gels and tinctures. However, there 
is no information regarding the harpagoside content in these 
formulations along with the data establishing its safety and 
efficacy. Therefore, with increase in the utilization of root 
extract as complimentary treatment for painful arthritis, low 
back pain etc there is a need to standardize the root extract 
in terms of harpagoside content and physicochemical 
properties. 
Hence, the present investigation was aimed to characterize 
the commercially available root extract of devils claw for its 
structural, physicochemical properties and to develop an 
accurate and precise RP-HPLC-PDA method for the 
estimation of harpagoside in the root extract. From the 
literature survey, it was found that only a few methods were 
reported on the estimation of harpagoside in the root extract 
18, 19. However, these methods may not be applicable for the 
routine quality control analysis involving large number of 
samples because of their higher retention times thereby 
requiring more amounts of organic solvents which is not 
economical. Hence, there is a need to develop simple and 
economical RP-HPLC-PDA method with shorter retention 
time that is suitable for routine quality control analysis. Also, 
no reports were published till date on evaluating the 
morphological, structural, physicochemical properties of 
harpagoside, which are considered as the key parameters for 
the formulation development.  
Therefore, in the present investigation an attempt was made 
to develop a simple and economical RP-HPLC-PDA method 
for the estimation of harpagoside in the commercial root 
extract and in oral powder formulations of devil’s claw and 
to characterize harpagoside for its morphological, structural 
and physicochemical properties using SEM, FT-IR, and DSC 
analysis. 
MATERIALS AND METHODS 
Materials 
Harpagoside analytical standard was purchase from Sigma 
Aldrich (Lot Number: BCBT7346). Commercial root extract 
of devils claw was purchased for Vigorous tech, China. 
Formic acid, Methanol and water are of HPLC grade procured 
from Merck, Mumbai, India.  
Instrumentation and Chromatographic Conditions 
The analysis was performed on a Shimadzu Prominence 
HPLC system consisting of DGU-20A3 degasser, SIL-20ACHT 
auto sampler and a LC-20AD binary pump system interfaced 
with a PDA detector. Phenomenex Kinetex XB column 
(150x4.6mm, 5µ) was used as stationary phase with 
methanol: 0.02% formic acid (60:40 v/v) as mobile phase 
composition. The mobile phase was sonicated prior to the 
analysis to remove any entrapped air bubbles and pumped at 
a flow rate of 1mL/min in isocratic mode. The quantification 
was performed with an injection volume of 20µL by 
monitoring the eluents at 280 nm using PDA detector. LC 
solution software was used for data acquisition and 
processing. 
Extraction and Estimation of Harpagoside in The Dried 
Root Extract  
The extraction of the harpagoside from the root extract was 
carried out as per the method described in European 
pharmacopeia 17 using water, methanol and a combination of 
water and methanol (50:50 v/v) as extracting solvents. 
Accurately weighed 350mg of extract was transferred to 
100mL volumetric flasks each and 50mL of respective 
solvents were added to them. After vortexing for 5 min the 
contents were sonicated for about 10 min using ultrasonic 
bath sonicator at room temperature and the final volume 
was made up to the mark with the respective solvents. The 
samples were then centrifuged at 15,000 rpm for 3min and 
the supernatant was separated and analysed by the RP-
HPLC-PDA method for the harpagoside content. 
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Preparation of Stock and Calibration Standards of 
Harpagoside 
Stock solution of harpagoside was prepared by dissolving 
accurately weighed 5mg of harpagoside analytical standard 
in 5mL of methanol to get a stock solution of 1mg/mL. From 
the stock solution suitable dilutions were made to prepare 
calibration standards in the concentration range of 0.2 to 
4µg/mL.  
Method Validation 
The chromatographic conditions employed in the present 
investigation were validated for parameters like specificity, 
linearity, precision, system suitability etc as per the ICH Q2 
(R1) guidelines 20 as follows: 
Linearity 
Linearity of the method was established by injecting the 
prepared calibration standards (n=3) over a concentration 
range of 0.2 to 4.0µg/mL and the obtained peak areas were 
used for construction of calibration plot. Form the resultant 
data, parameters such as slopes, intercepts and regression 
equations were calculated. 
Precision 
System precision was evaluated by injecting the harpagoside 
standard (1µg/mL) taken from the same aliquot for six times 
and percent relative standard deviation (% RSD) for peak 
areas and retention times were computed. The percent RSD 
for peak areas and retention times ought to be less than 2. 
Method precision was performed by injecting six replicates 
of sample solution and the percent RSD for peak area and 
retention times were calculated. 
Accuracy 
In the present investigation standard addition method was 
employed for the determination of accuracy. The method 
involves the addition of the known concentration of the 
standard at three levels (80, 100 and 120%) to the known 
concentration of sample solution. From the data obtained the 
percent RSD and percent recovery was calculated for each 
level of addition. 
Specificity 
Specificity of an analytical method determines its ability to 
measure accurately and specifically the analyte of interest in 
presence of other components that are expected to be in the 
sample matrix. It is determined by comparing the 
chromatograms of blank, the harpagoside standard and 
sample and observed for any interference at the retention 
time of the harpagoside.  
Limit of Detection (LOD) and Limit of Quantification 
(LOQ)  
The LOD and LOQ were calculated from the data obtained 
from the standard calibration curve using the following 
equation: 
LOD= 3.3xσ/m; LOQ= 10xσ/m 
Where ‘σ’ is the standard deviation of the responses and ‘m’ 
is the slope of the calibration curves. 
Robustness 
Robustness of the analytical method was evaluated by 
making small deliberate changes (± 2%) to the optimized 
chromatographic conditions like flow rate, mobile phase 
composition and wavelength. The harpagoside standard 
solution (1µg/mL) was injected for each minor change and 
the system suitability parameters were noted at each change. 
The parameters should be within the specified limits for the 
method to be robust. 
System Suitability 
System suitability tests were performed by injecting the 
increase volumes (10-50µL) of same concentration of 
harpagoside standard (1µg/mL) and observed for the 
changes in the parameters such as retention times, tailing 
factor and theoretical plate numbers with increase in 
injection volume. 
Stability of the Stock Solution 
Stock solution stability in methanol was evaluated by 
injecting the prepared stock solution at different time 
intervals over a period of 24hr and observed for the changes 
in the peak areas and retention times with respect to the 0hr 
sample. Throughout the study the stock solution was stored 
at 2-8°C. 
FT-IR Analysis 
FT-IR analysis was carried out on FT-IR spectrometer 
(Bruker, Germany) attenuated with ATR fitment. The extract 
was placed on the ATR crystal (zinc selenium crystal) and 
the spectra were recorded over a wavenumber range of 
4000-500 cm-1 at a resolution of 1.0 cm-1. 
DSC Analysis 
DSC analysis was carried out using Differential scanning 
calorimeter (Shimadzu DSC-60, Japan). 4mg of the extract 
was weighed and placed on to the aluminium pan and heated 
from 30-300°C at a rate of 10°C per minute. An empty 
aluminium pan was used as reference. Nitrogen gas at flow of 
100mL/min was used to maintain the inert atmosphere.  
Morphological characterization 
Morphological Properties 
The morphological properties like colour, appearance of the 
extract were observed visually. The particle morphology of 
root extract was assessed by observing the extract under 
trinocular microscope (Olympus-CH20i) with different 
magnifications like 10X and 40X and the photomicrographs 
were taken. 
SEM Analysis 
The surface morphology of the dried root extract powder 
was further established using scanning electron microscope 
(SEM-JEOL, JSM-840A, Japan). The samples was placed on 
the SEM slab and analysed with a voltage of 25 KV. The 
images were taken with 100, 250 and 500 fold 
magnifications.  
Preparation of Flavoured Powders of Devils Claw Root 
Extract 
Flavoured powder (both effervescent and non-effervescent) 
formulations of root extract were prepared as per the 
formulae given in Table 1 to batch size of 5g per sachet. 
Extract equivalent to 30mg of harpagoside was accurately 
weighed and mixed thoroughly with the excipients using 
spatula in watch glass and stored in aluminium foil pouches 
until use. The amount of root extract taken for the 
preparation of powder formulations was selected on the 
basis of clinical studies reported in the literature [15, 16] 
stating that the daily administration of more than 50mg of 
harpagoside is required to achieve the desired therapeutic 
benefits of the extract. The prepared formulations were then 
analysed by the RP-HPLC-PDA method for the harpagoside 
content in the formulations. 
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Table 1: Composition of flavoured powders of devil’s claw root extract 
Ingredients (g) 
Formulae (5g sachet) 
F1* F2 F3 
Devils claw root extract 1.88 1.88 1.88 
Citric acid 0.5 - - 
Tartaric acid 1.0 - - 
Sodium bicarbonate 1.5 - - 
Microcrystalline cellulose - 0.75 0.75 
Mannitol - 2.25 - 
Lactose - - 2.25 
Magnesium stearate - 0.05 - 
PEG-4000 - - 0.05 
Colouring agent 0.05 0.05 0.05 
Flavouring agent 0.05 0.05 0.05 
           * Effervescent powder formulation. 
Stability Studies  
Stability studies of the prepared powder formulations were 
carried out. The formulations were stored in aluminium foil 
pouches, sealed and stored 40°C, 75±5% RH for 6 months. 
During this period the formulations were observed for their 
morphological properties like texture, colour etc and also 
analysed for the harpagoside content by RP-HPLC-PDA 
method. 
RESULTS AND DISCUSSION 
Analytical Method Development  
In the initial step of the method development, the 
chromatographic separations were carried out on 
Phenomenex Kinetex XB C18 column (150x4.6mm, 5µ) using 
methanol: 0.02% formic acid (50:50 v/v) as mobile phase 
composition at 1mL/min flow rate. However, under these 
conditions no peak was eluted even after 30min of run time. 
Hence, further trails were carried out by altering the mobile 
phase ratios and keeping the remaining parameters the 
same. With 70:30 v/v ratio of methanol: 0.02% formic acid, 
harpagoside was eluted at 3.1 min whereas, with 65:30 v/v 
and 60:40 v/v ratios, harpagoside was eluted at 4.2 and 5.3 
min respectively. Among the three mobile phase ratios, the 
ratio of 60:40 v/v gave good peak shape, symmetry and 
theoretical plate number compared to the other two ratios. 
Hence, the ratio of 60:40 v/v methanol: 0.02% formic acid 
was selected as mobile phase composition. 
Further trails were carried out in order to select the suitable 
diluent that can maximize the elution capacity of the analyte 
with minimum or no interferences. Trails were carried out 
by preparing samples using formic acid (0.02%), water and 
methanol as diluents. From the results obtained, it was found 
that sample prepared with water as diluent showed 
maximum elution strength with higher peak areas and 
theoretical plate numbers compared to formic acid and 
methanol. Hence, water was selected as diluent for further 
analysis. 
Overall, Phenomenex Kinetex XB C18 column (150x4.6mm, 
5µ) as stationary phase, methanol: 0.02% formic acid (60:40 
v/v) as mobile phase composition and water as diluent were 
found to be best suited conditions for the analysis of 
harpagoside. The chromatogram of harpagoside analytical 
standard obtained with the optimized conditions was shown 
in Figure 2A along with the peak purity indices and UV 
spectra in Figure 2B and 2C respectively. 
 
 
Figure 2: A) Chromatogram of Harpagoside standard (1µg/mL), B) Peak purity index, C) UV spectra of Harpagoside 
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Estimation of Harpagoside in the Dried Root Extract 
The amount of harpagoside in different extraction samples 
was estimated using the developed RP-HPLC-PDA method. 
The extraction was carried out in different solvents like 
water, methanol and combination of water: methanol (50:50 
v/v) in order to determine their extraction efficiencies. From 
the results obtained, it was found that highest percentage of 
harpagoside (1.6) was extracted with water as extraction 
solvent compared to water: methanol (50:50 v/v) and 
methanol. Also, the retention time of the peak obtained with 
the root extract was matched with the retention time of 
harpagoside analytical standard, demonstrating that the 
peak obtained with the extract can be ascertained to the 
harpagoside. Overall, from the results obtained it can be 
concluded that the commercial root extract of devil’s claw 
used in the present study contains 1.6% of harpagoside and 
complies the European pharmacopeia specification 17 (i.e. 
the dried root extract should contain a minimum of 1.5% of 
harpagoside).  
Method Validation 
The developed RP-HPLC-PDA method was validated as per 
the ICH guidelines and the results of the validation were as 
follows: 
Linearity 
The calibration curve obtained by plotting concentrations 
against peak area was evaluated for the correlation 
coefficient. The response was linear across the selected 
concentration range of 0.2 to 4.0µg/mL with a correlation 
coefficient (R2) greater than 0.998 (Table 2). 
Precision 
Both system and method precision was evaluated and the 
results were shown in Table 2. The results indicate 
acceptable sample stability and method consistency with less 
than 2% RSD’s for peak areas and retention times. 
 
Accuracy 
The accuracy was determined by standard addition method 
and the percent recoveries of the added standard to the 
sample was calculated and was found to be 98.52-100.4 and 
the percent RSD’s was less than 2 indicating the accuracy of 
the method to the claimed amount (Table 2). 
Specificity 
The specificity of the analytical method was determined by 
comparing the chromatograms of blank, harpagoside 
standard and sample. For the overlay of chromatograms it 
can be inferred that there was no interferences of impurities 
or sample matrix at the retention times of harpagoside 
indicating that the method was specific for the detection of 
harpagoside (Figure 3). Also, the peak purity index of the 
standards and samples was greater than 0.999 further 
conforming the specificity of the developed method. 
 
Figure 3: Overlay of Chromatograms of A) Blank, B) 
Harpagoside standard C) Sample with base shift 
Limit of Detection (LOD) and Limit of Quantification 
(LOQ)  
In the present investigation LOD and LOQ was calculated 
from the standard deviation of the responses and the slop of 
the regression equation from the calibration curve. The LOD 
and LOQ were found to be 0.017µg/mL and 0.052µg/mL 
respectively (Table 2). 
 


















System Precision (n=6) Average Peak area of the 
standard (%RSD) 44680.67 (0.93) 
Method precision 
(n=6) 
Average Peak area of the sample 
(%RSD) 
55287.33 (1.08) 
Limit of detection (LOD) 
- 0.017µg/Ml 




The robustness of the method was determined by making 
small deliberate changes (±2%) to the optimized 
chromatographic conditions like mobile phase ratio, flow 
rate and detector wavelength. Form the results, it was found 
that altering the mobile phase ratios and flow rate resulted 
in significant change in retention times whereas, no 
difference was observed with change in detector wavelength. 
However, no significant changes in remaining 
chromatographic parameters were observed indicating that 
the developed method was robust under these changed 
conditions. 
Nalluri et al                                                                                                                      Journal of Drug Delivery & Therapeutics. 2019; 9(2):38-46 
ISSN: 2250-1177                                                                                  [43]                                                                                 CODEN (USA): JDDTAO 
System Suitability 
System suitability tests were performed by injecting increase 
volumes of same concentration of harpagoside standard 
(1µg/mL) and the percent RSDs for tailing factor, retention 
times and theoretical plate number were calculated. From 
the results it was observed that the percent RSDs for all the 
parameters were well within the limits and the developed 
conditions were found to be suitable for analysis of 
harpagoside. 
Stock Solution Stability 
The stability of the harpagoside stock solutions was 
determined by analysing the samples under refrigeration 
(8±1°C) at different time intervals up to 24 hours. No 
significant difference was observed in the peak areas, 
retention times and other chromatographic parameters of 
the samples compared to the initial sample. Also, no 
variation in the harpagoside content was observed when 
compared to the initial sample indicating that the solutions 
were stable under the employed conditions for 24-hour time 
period. 
FT-IR Analysis 
The FT-IR spectra of devil’s claw root extract was shown in 
Figure 4A. The spectra showed characteristic bands at 
1145.37 cm-1 (-C-O stretching), 1621.00 cm-1 (-C=O 
stretching), 2934.21 cm-1 (-C=C stretching), 3253.00 cm-1 (-
O-H stretching) wavenumbers. Along with these the 
fingerprint region of the IR spectra also showed prominent 
band at 969.24 cm-1 which can be attributed to the sugar 
moiety that is attached to the iridoid glycoside ring. Also, the 
spectra of the root extract was in accordance with the FT-IR 
spectra of the harpagoside analytical standard (Figure 4B) 
conforming the presence of harpagoside in the root extract. 
Together with the molecular structure of the harpagoside 
(Figure 1) and the results from the FT-IR analysis the 
characteristic bands observed can be assigned to the ether 
linkages (1145.37 cm-1), ester linkages (1621.00 cm-1) and 
phenolic OH groups (3253.00 cm-1) that are present in the 
harpagoside. (Table 3). 
 
 
Figure 4: FT-IR spectra of A) Harpagoside analytical standard, B) Devils claw root extract 
Table 3: FT-IR Spectral data of Devils claw root extract 





Ether (C-O) Stretching 1300-1000 1145.37 
Ester (C=O) Stretching 1735-1600 1621.00 
Phenolic O-H Stretching 3600-3200 3253.00 
Sugar moiety Stretching 1000-825 969.24 
 
DSC Analysis 
The DSC thermogram of the root extract was shown in Figure 
5. The thermogram revealed no significant exothermic or 
endothermic peaks apart from small endothermic peak at 
209.9°C. The absence of the significant peaks suggest that the 
root extract is more of amorphous in nature rather than the 
crystalline.
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The results from the SEM analysis (Figure 6) also revealed 
the spherical morphology of the particles in the root extract 
with smooth and wrinkled surfaces. Also, the extract was 
found to be composed of particles with various sizes ranging 
from 5µm to 55µm.  
 
 
Figure 6: Scanning electron micrographs of root extract taken at 100 fold (A) 250 fold (B) and 500 fold (C) magnifications. 
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Preparation of Flavoured Powders of Devils Claw Root 
Extract 
The flavoured powders (effervescent and non-effervescent) 
were prepared as per the formulae given in Table 1 to a 
batch size of 5g per sachet. The required ingredients were 
thoroughly mixed using spatula in dry and clean watch glass 
(Figure 7) until all the ingredients were uniformly mixed. 
The powder mixture was then packed in aluminium foil 
pouches and stored in desiccator until use. The prepared 
powders were intended to be administered thrice a day by 
dissolving them in full glass of water. The formulations 
dissolved quickly in water and devoid of any undissolved 
matter making them easier to administer. The harpagoside 
content in the powder formulations was analysed by the 
developed RP-HPLC-PDA method and was found to be 98.7, 
98.3 and 99.5 percent respectively for F1, F2 and F3 
formulations indicating that the developed analytical method 




Figure 7: Different formulations of the root extract along with the control (extract alone) 
 
Stability Studies 
The prepared formulations were stored in aluminium foil 
pouches at 40°C with relative humidity of approximately 
75±5% for 6 months and observed for the harpagoside 
content along with the morphological properties. No change 
in colour and texture of the powder was observed 
throughout the observation period and especially no 
formation of powder lumps was observed. All the 
formulations showed more than 98-101% of harpagoside 
content even after 6months time period indicating that the 
formulations were stable throughout the observation period. 
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CONCLUSION 
In consideration of the increase in the commercial use of the 
devils claw root extract and need for its standardization the 
results from the present investigation can form basis to 
establish fundamental characteristics of the root extract that 
can be used for further establishment of the standardization 
parameters to ensure quality, safety and reproducibility of 
the devils claw formulations. The developed RP-HPLC-PDA 
method provides rapid and precise estimation of 
harpagoside in the root extract with simple mobile phase 
compositions and faster elution times. The results from the 
FT-IR, DSC and SEM analysis can be used for establishing the 
structural, morphological and physicochemical 
characteristics of the root extract which are the important 
factors in the development of devils claw formulations. 
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